When to get seasonal COVID vaccines
- Mark Ziats

- Aug 9
- 3 min read

Interestingly, as with all things in medicine, there may not be a right answer to this question.
One intriguing study showed this was very location specific and felt due to many factors such as the relative humidity in a region, etc:
Jeffrey P Townsend, Hayley B Hassler, Alex Dornburg, Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection, Clinical Infectious Diseases, Volume 80, Issue 2, 15 February 2025, Pages 316-322
In general, the best timing is before the fall–winter respiratory virus season, with the most recent updated COVID-19 vaccine given at least 2 months after the last COVID-19 dose; adults ≥65 years and those with moderate/severe immunocompromise may receive additional doses, also spaced ≥2 months apart.[1-4]
Key points:
• Rationale: Protection against medically attended illness and hospitalization is highest in the first 1–2 months after vaccination and wanes thereafter; aligning vaccination ahead of peak transmission maximizes benefit.[2][4-7]
• Populations: CDC/ACIP recommend updated vaccination annually for all persons ≥6 months of age; schedules are consistent across ages, and coadministration with other routine vaccines is acceptable and encouraged when due (American Academy of Family Physicians summary of ACIP schedules; American Academy of Pediatrics for pediatric populations).[3][8]
• Immunocompromised and ≥65 years: Additional 2023–2024 doses (≥2 months apart) are recommended or may be considered to sustain protection against hospitalization.[1][4]
• For recent SARS‑CoV‑2 infection, defer until recovery and consider timing within these intervals; specific intervals after infection may vary and are not well studied.[2][4]
These recommendations are supported by observational VE data showing substantial short-term protection of updated formulations against ED/UC encounters and hospitalization, with measurable waning over time.[1-2][4-7]
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
1. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Hospitalization Among Adults Aged ≥18 Years With Immunocompromising Conditions - VISION Network, September 2023-February 2024. Link-Gelles R, Rowley EAK, DeSilva MB, et al. MMWR. Morbidity and Mortality Weekly Report. 2024;73(12):271-276. doi:10.15585/mmwr.mm7312a5.
2. Interim Effectiveness of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years - VISION and IVY Networks, September 2023-January 2024. DeCuir J, Payne AB, Self WH, et al. MMWR. Morbidity and Mortality Weekly Report. 2024;73(8):180-188. doi:10.15585/mmwr.mm7308a5.
3. ACIP Approves 2023 Child/Adolescent and Adult Immunization Schedules. American Academy of Family Physicians. Practice Guideline
4. Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults. Link-Gelles R, Rowley EAK, Irving SA, et al. JAMA Network Open. 2025;8(6):e2517402. doi:10.1001/jamanetworkopen.2025.17402.
5. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022. Johnson AG, Linde L, Ali AR, et al. MMWR. Morbidity and Mortality Weekly Report. 2023;72(6):145-152. doi:10.15585/mmwr.mm7206a3.
6. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. Tenforde MW, Weber ZA, Natarajan K, et al. MMWR. Morbidity and Mortality Weekly Report. 2023;71(53):1637-1646. doi:10.15585/mmwr.mm7153a1.
7. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022. Surie D, DeCuir J, Zhu Y, et al. MMWR. Morbidity and Mortality Weekly Report. 2022;71(5152):1625-1630. doi:10.15585/mmwr.mm715152e2.
8. COVID-19 Vaccines in Infants, Children, and Adolescents. Pediatrics. 2022;150(3):e2022058700. doi:10.1542/peds.2022-058700.

Comments